March 28, 2018 / 11:46 AM / 8 months ago

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

March 28 (Reuters) - Mersana Therapeutics Inc:

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

* Q4 LOSS PER SHARE $0.61

* Q4 EARNINGS PER SHARE VIEW $-0.50 — THOMSON REUTERS I/B/E/S

* ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2

* COLLABORATION REVENUE FOR Q4 2017 WAS ABOUT $3.3 MILLION VERSUS $12.0 MILLION FOR SAME PERIOD IN 2016

* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE $125.2 MILLION

* MERSANA THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below